Lu anti-pharmaceutical subsidiary was certified as an injection drug of ammonia hydrochloride

On November 18, Lu Anti-Pharma announced that the holding subsidiary Shandong Lu Anti-Pharmaceutical Group Cyt Co., Ltd. recently received the State Drug Administration issued a hydrochloric acid bromoso injection "Drug Registration Certificate."
hydrochloric acid bromoso injection is a generic drug developed by Shandong Lu Anti-Pharmaceutical Group Cyt Co., Ltd., and the adaptive disorder is suitable for acute and chronic lung diseases with abnormal sputum secretion and poor sputum discharge function.
e.g. acute exacerbation of chronic bronchitis, sputum treatment of wheezing bronchitis and bronchial asthma, preventive treatment of lung complications after surgery, treatment of respiratory distress syndrome (IRDS) in premature infants and newborns.
this product is a domestic imitation, Shandong Lu Anti-Pharmaceutical Group Cyt Co., Ltd. first submitted the production application for this product on November 20, 2013 (acceptance number: CYHS1301785 Lu CYHS1301786 Lu).
date of this announcement, the cumulative investment in research and development of hydrochloric acid bromoline injections was approximately RMB822.35 million.
hydrochloride bromosoline, developed by Grigg Ingham, was first listed in Germany in 1979, in Chile and Hong Kong in 1984, and subsequently in more than 20 countries, including Italy, Japan, Mexico, Sweden and Australia.
2000 in China import registration, the commodity name "Mucosolvan", specifications: 2ml: 15mg.
according to the website of the Drug Review Center of the State Drug Administration, as of the date of this announcement, 75 domestic companies had obtained hydrochloride bromosot injection batches.